Literature DB >> 19007996

What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies.

Abebaw Fekadu1, Sarah C Wooderson, Kalypso Markopoulo, Catherine Donaldson, Andrew Papadopoulos, Anthony J Cleare.   

Abstract

BACKGROUND: Treatment-resistant depression (TRD) is relatively common and accounts for a large proportion of the overall burden caused by depression. We conducted a systematic review of outcome studies of TRD in order to summarise findings on the longer term outcome of TRD and make recommendations.
METHODS: Studies were identified through MEDLINE (1960--June Week 1 2008), EMBASE (1974--June Week 1 2008) and PsycINFO (1967--June Week 1 2008) searches. We included studies that followed adults with highly probable TRD for a minimum of 6 months. Statistical analyses were conducted on selected outcome variables whenever possible. Methodological heterogeneity of studies prohibited formal meta-analysis.
RESULTS: We identified nine outcome studies with a total of 1279 participants and follow-up duration of between 1 and 10 years. In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission. For those with a more protracted illness, the probability of recovery within 10 years was about 40%. TRD was also associated with poorer quality of life and increased mortality. LIMITATIONS: Included primary studies were heterogeneous.
CONCLUSIONS: TRD is associated with poorer clinical outcome, particularly among those who require multiple antidepressant medications. The main limitations of the review arise from the variability in recruitment procedures, definitions and outcome assessments of the original studies. We recommend further follow-up studies of carefully identified samples in order to gain a more detailed understanding of this domain of depression and plan effective interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007996     DOI: 10.1016/j.jad.2008.10.014

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  70 in total

1.  Predicting recurrence of depression.

Authors:  Paul Kurdyak; John Cairney
Journal:  CMAJ       Date:  2011-10-24       Impact factor: 8.262

Review 2.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 3.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

4.  Relapse following successful electroconvulsive therapy for major depression: a meta-analysis.

Authors:  Ana Jelovac; Erik Kolshus; Declan M McLoughlin
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

5.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

6.  The ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception.

Authors:  Carl Erik Fisher; Laura B Dunn; Paul P Christopher; Paul E Holtzheimer; Yan Leykin; Helen S Mayberg; Sarah H Lisanby; Paul S Appelbaum
Journal:  Ann N Y Acad Sci       Date:  2012-07-19       Impact factor: 5.691

7.  Quality of life across domains among individuals with treatment-resistant depression.

Authors:  Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey
Journal:  J Affect Disord       Date:  2018-09-19       Impact factor: 4.839

Review 8.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

9.  Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.

Authors:  Oliver Vranjkovic; Garrett Winkler; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2018-05-24       Impact factor: 7.853

Review 10.  Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).

Authors:  Mark S George; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.